DNA Changes That Affect Vitamin D Metabolism in Patients With Colorectal Cancer Receiving Vitamin D Supplements

Colorectal Cancer Clinical Trial

Official title:

Identification of 24-Hydroxylase Polymorphisms and Splicing Variants That Modulate Vitamin D Oxidative Metabolism and Serum Pharmacokinetics in Patients With Colorectal Cancer on Cholecalciferol Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00550563
• Other study ID #: I 99207
• Secondary ID: RPCI-I-99207
• Status: Completed
• Phase: N/A
• First received: October 25, 2007
• Last updated: March 31, 2017
• Start date: August 2007
• Est. completion date: July 2010

Study information

• Verified date: March 2017
• Source: Roswell Park Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This clinical trial is studying changes in DNA that affect vitamin D metabolism in patients with colorectal cancer receiving vitamin D supplements.

Description:

OBJECTIVES:

• To identify CYP24 single nucleotide polymorphisms (SNPs) using peripheral blood mononuclear cell genomic DNA from patients with colorectal cancer receiving cholecalciferol supplementation.

• To evaluate the effects of these CYP24 SNPs on baseline serum vitamin D_3 metabolites (25-D_3, 24,25-D_3, and 1,25-D_3), and parathyroid hormone levels (PTH).

• To evaluate the effects of these CYP24 SNPs on serum vitamin D_3 metabolites and PTH levels during cholecalciferol treatment.

• To examine CYP24 splicing, protein expression, and enzyme activity at baseline and during cholecalciferol treatment.

• To determine the relationship, if any, between serum cholecalciferol pharmacokinetic parameters and CYP24 SNPs, splicing variants, and enzyme activity.

OUTLINE: Patients receive oral cholecalciferol 2000 IU once daily for 1 year. Patients without response to vitamin D supplementation (serum 25-D_3 level < 32 ng/mL) by 6 months will have their cholecalciferol dose increased to 4000 IU once daily.

Blood is collected at baseline and on days 14, 30, 60, 90, 180, 270, and 360. Peripheral blood mononuclear cells for CYP24 genotyping, protein expression, enzyme activity, and splicing variants are analyzed by polymerase chain reaction (PCR), western blot, high performance liquid chromatography, and reverse transcriptase PCR, respectively. Serum is analyzed for vitamin D_3 metabolite levels (by radioimmunoassay), calcium (to monitor for hypercalcemia), and parathyroid hormone assays (to measure vitamin D effect).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: July 2010
• Est. primary completion date: April 2009
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Prior or current documented diagnosis of colorectal cancer

• All stages

• 25OH-D3 level < 50 ng/mL

PATIENT CHARACTERISTICS:

• ECOG performance status 0-2

• Life expectancy > 6 months

• Serum creatinine < 2.0 mg/dL

• Serum bilirubin < 2.0 mg/dL

• No prior or current hypercalcemia (defined as albumin corrected serum calcium < 10.2 mg/dL)

• No known contraindication for vitamin D supplementation

• No genitourinary stones within the past 5 years

• No severe comorbid conditions such as uncompensated heart failure or active infection

PRIOR CONCURRENT THERAPY:

• No supplemental vitamin D beyond what is provided through the study

• At least 2 months since prior vitamin D supplementation exceeding 800 International Units (IU)

• Nondietary vitamin D supplements should not have exceeded 800 IU/day within the past 2 months

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

Intervention

Dietary Supplement:
• cholecalciferol
Oral

Genetic:
• polymerase chain reaction
companion study
• polymorphism analysis
companion study
• protein expression analysis
companion study
• reverse transcriptase-polymerase chain reaction
companion study
• western blotting
companion study

Other:
• high performance liquid chromatography
companion study
• laboratory biomarker analysis
companion study
• pharmacological study
companion study

Procedure:
• adjuvant therapy
Additional therapy
• immunoscintigraphy
additional testing

Locations

Country	Name	City	State
United States	Roswell Park Cancer Institute	Buffalo	New York

Sponsors (1)

Lead Sponsor	Collaborator
Roswell Park Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identification of CYP24 single nucleotide polymorphisms (SNPs)		Baseline, days 14, 30, 60, 90, 180, 270, 360
Primary	Effect of CYP24 SNPs on baseline serum vitamin D3 metabolites (25-D3, 24,25-D3, and 1,25-D3), and parathyroid hormone levels (PTH)		At baseline
Primary	Effect of CYP24 SNPs on serum vitamin D3 metabolites and PTH levels during cholecalciferol treatment		Baseline, days 14, 30, 60, 90, 180, 270, 360
Primary	CYP24 splicing, protein expression, and enzyme activity at baseline and during cholecalciferol treatment		Baseline, days 14, 30, 60, 90, 180, 270, 360
Primary	Relationship between serum cholecalciferol pharmacokinetic parameters and CYP24 SNPs, splicing variants, and enzyme activity		Baseline, days 14, 30, 60, 90, 180, 270, 360